media – Page 47 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HPV vaccine sales fell short of expectations, with Wantai Biopharma turning profit into loss in the first half of the year

Recently, Wantai BioThe company disclosed its 2025 semi-annual report, showing that its operating income in the first half of the year was 844 million yuan, a year-on-year decrease of 38.25%; its net profit attributable to shareholders of the parent company turned from profit to loss to -144 million yuan, a year-on-year decrease of 155.3%; its non-net profit was as low as -243 million yuan, a year-on-year decrease of 481.93%. Regarding the decline in revenue and net profit, Wantai Biological explained that it was mainly due to the fact that the company’s vaccine segment was affected by market adjustments, government procurement and the expansion of the age limit for the nine-valent HPV vaccine, resulting in sales falling short of expectations and a decline in revenue from the vaccine segment compared with the same period last year. Regarding the company’s sharp decline in first-half performance and subsequent boosting measures, a reporter from ...
- Source: drugdu
- 388
- August 28, 2025
Lepu Medical’s subsidiary completes first dose in Phase II clinical trial of innovative drug MWN109

On August 25, Lepu Medical(300003) announced that its holding subsidiary, Minwei Bio, independently developed an innovative drugMWN109 injection is currently undergoing Phase II clinical trials for the treatment of overweight or obesity, and the first subject was successfully dosed recently. The drug is a GLP-1/GIP/GCG receptor triple agonist with global intellectual property rights .MWN109 injection is designed to effectively control blood sugar and reduce weight by stimulating pancreatic beta cells to secrete insulin and increase satiety. MWN109 injection received clinical trial approval from the National Medical Products Administration in November 2024. A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial has been initiated, primarily investigating the effectiveness of different doses of MWN109 injection in reducing weight over a 24-week period in non-diabetic overweight or obese participants. The primary endpoint of the study is the percentage change in body weight compared to baseline after 24 weeks of dosing. The company reminds ...
- Source: drugdu
- 85
- August 28, 2025
CEIVD Beijing

Organiser: China Healthcare Industry Association, Chinese Medical Exchange Association Time：September 17 – September 19, 2025 address：No. 6, North Third Ring Road East, Chaoyang District, Beijing Exhibition hall：China International Exhibition Center (Chaoyang Hall) Product range: Clinical Testing Equipment: Biochemical analyzers, immunoassay analyzers, bacterial analyzers, urine analyzers, microbiological analyzers, electrolyte analyzers, hematology analyzers, hemodialysis machines, enzyme-linked immunosorbent assay (ELISA) readers, chromatographs, PCR instruments, etc. Clinical Testing Reagents: In vitro diagnostic reagents, rapid diagnostic reagents, electrolyte reagents, hematology reagents, blood coagulation reagents, blood typing reagent kits, lipid reagents, biochemical reagents, chemiluminescent reagents, dry chemistry test strips, reagents for chlamydia and methamphetamine detection, protein detection reagents, infectious disease detection reagents, tumor marker reagents, human gene detection reagents, immunohistochemistry and human tissue cell reagents, biochips, vitamin determination reagents, cell and tissue chemical staining agents, autoimmune diagnostic reagents, microbiological testing reagents, and other diagnostic reagents. Blood Transfusion Products: Blood collection and supply instruments and equipment, ...
- Source: drugdu
- 250
- August 28, 2025
Sinovac expands into trauma field; adsorbed tetanus vaccine receives drug registration approval

China Business Network reported on August 27 that on August 25, the adsorbed tetanus vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Beijing Kexing Holdings (Group) Co., Ltd., obtained the “Drug Registration Certificate” issued by the National Medical Products Administration (Approval Number: National Medicine Standard S20250048), which will provide more options for tetanus prevention. Sinovac’s adsorbed tetanus vaccine uses an aluminum hydroxide adjuvant with a particle size of only 300 nanometers (compared to traditional adjuvants of 1-10 microns), which improves antigen adsorption efficiency and significantly enhances formulation stability. By upgrading the purification process, the tetanus vaccine concentrate has better immunogenicity. According to the “Guidelines for the Diagnosis and Treatment of Non-Neonatal Tetanus (2024 Edition)”, tetanus remains a serious public health problem in countries and regions where immunization programs are not fully implemented. It is estimated that there are approximately 1 million cases of tetanus and 300,000 ...
- Source: drugdu
- 113
- August 27, 2025
Gilead expands its cell therapy portfolio

Recently, Kite, a subsidiary of Gilead, announced that it will acquire the biotechnology company Interius BioTherapeutics for US$350 million in cash. This strategic layout marks Gilead’s opening up of a new frontier in the field of cell therapy. Cell therapy, a frontier of innovation in the biopharmaceutical field, is developing at an astonishing pace. While traditional CAR-T therapy has achieved remarkable results in treating hematologic malignancies, it is limited by complex procedures and high costs. Kite’s acquisition of Interius is driven by its pioneering work in in vivo CAR-T therapy. Interius’s in vivo CAR-T technology innovatively eliminates the tedious in vitro steps of traditional therapies, opening up new avenues for the convenience and accessibility of cell therapy and injecting strong technological vitality into Gilead. Interius’s technology platform, leveraging its modularity, can be efficiently adapted to diverse disease areas, enabling scalable production. INT2104, the lead product in its R&D pipeline, is ...
- Source: drugdu
- 123
- August 27, 2025
Tariffs on medicines will be imposed soon

On August 25, local time, it was reported that US President Trump said that he would reduce drug prices to 1/1400 to 1/1500 of the current price, and would deal with the cost figures of US drug prices. Tariffs on medicines will soon be imposed. https://finance.eastmoney.com/a/202508263494050365.html
- Source: drugdu
- 94
- August 27, 2025
my country’s pharmaceutical industry ranks second in the world

Yang Sheng, deputy director of the National Medical Products Administration, recently stated that China’s pharmaceutical industry is currently ranked second in the world, with innovative drugsThe number of projects under research accounts for about 30% of the world’s total. Yang Sheng said that to complete the goals and tasks of the 14th Five-Year Plan with high quality and ensure the safety and effectiveness of people’s use of medicines, work should be mainly carried out in three aspects: comprehensively strengthening the bottom line of drug safety, supporting the high-quality development of the pharmaceutical industry throughout the entire chain, and fully guaranteeing the people’s drug needs. In terms of building a solid bottom line for drug safety in all aspects, my country has strengthened dynamic supervision covering the entire life cycle of drugs, established and improved a drug safety risk consultation mechanism, focused on key links such as online drug sales, contract ...
- Source: drugdu
- 89
- August 27, 2025
Novartis, BioArctic Reach Deal to Develop BrainTransporter Therapy for Neurodegeneration

Novartis and BioArctic AB have entered into an option, collaboration, and license agreement to explore a potential new treatment for neurodegenerative disorders. The partnership will apply BioArctic’s proprietary BrainTransporter technology to enhance brain-targeted delivery of therapeutic agents, with the goal of generating a novel drug candidate for evaluation in preclinical and early research stages. How does the Novartis agreement expand BioArctic’s BrainTransporter strategy? Under terms of the deal, BioArctic will receive an upfront payment of $30 million during the initial research collaboration, during which it will generate a drug candidate combining BrainTransporter with a Novartis proprietary antibody. After reviewing the resulting data, Novartis may exercise an option to license the candidate, a step that would trigger additional potential payments to BioArctic of up to $772 million. The Swedish biotech would also be eligible for tiered mid–single-digit royalties on any eventual global product sales. If Novartis chooses to exercise the option, ...
- Source: drugdu
- 97
- August 27, 2025
Pig Lung Transplanted Into Man for 9 Days in Groundbreaking Study

TUESDAY, Aug. 26, 2025 (HealthDay News) — Doctors in China transplanted a genetically modified pig lung into a man, where it functioned for nine days, according to a new study published in the journal Nature Medicine. Researchers at Guangzhou Medical University’s First Affiliated Hospital performed the surgery on a 39-year-old man who had been declared brain-dead after a brain hemorrhage. His family gave consent for the procedure, CNN reported. This is believed to be the first attempt to transplant a pig lung into a human. While scientists see hope in this type of surgery, experts say it could take years before it’s an option for people who need lung transplants. The pig lung used in the transplant had six gene edits that were designed to reduce the risk of rejection. The donor pig was raised in a highly controlled, sterile environment. Doctors also gave the patient several medications to lower ...
- Source: drugdu
- 86
- August 27, 2025
【EXPERT Q&A】How to handle the filing for Class I medical device products?

Drugdu.com expert’s response: Medical Device Class I Product Filing Process I. Pre-Filing Preparation Confirm Product Classification Ensure the product falls within the scope of the Class I Medical Device Product Catalog or the In Vitro Diagnostic Reagent Classification Sub-Catalog. If the product is outside these catalogs, apply to the National Medical Products Administration (NMPA) for classification determination. Filing can proceed only after confirmation as a Class I medical device. Prepare Filing Documents The following core materials must be submitted (subject to local regulatory requirements): Filing Form: Completed and stamped with the enterprise’s official seal or signed by the legal representative. Enterprise Qualification Documents: Business license duplicate. Legal representative’s identification. Product Technical Documents: Product Technical Requirements (prepared per the Guidelines for Drafting Technical Requirements for Medical Devices), specifying functional and safety indicators, as well as testing methods. Product Inspection Report (self-tested or commissioned testing, including product information, testing basis, and results). Instructions for Use and Label Samples (compliant ...
- Source: drugdu
- 188
- August 27, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.